The combination of a FLT3 inhibitor with frontline intensive chemotherapy is the standard of care for fit adults with newly diagnosed FLT3-mutated AML, based on positive data from the RATIFY study that evaluated midostaurin—and, more recently, from the QuANTUM-First study evaluating quizartinib [14, 37]. Here, FLT3 is linked to acute myeloid leukemia.